GlobeNewsWire
26 Aug 2026, 05:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Addex Therapeutics has extended its cash runway into the fourth quarter of 2027. — For clinical-stage biotech firms, extending the timeline before the next funding need significantly reduces immediate insolvency risk and provides stability for R&D.
+0.60The company raised USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs via its At the Market (ATM) offering agreement. — While providing necessary liquidity, ATM offerings typically result in minor share dilution for existing holders.
+0.20The total number of outstanding shares (excluding treasury shares) increased to 210,292,217. — An increase in outstanding shares dilutes the earnings and ownership percentage of current shareholders.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company successfully raised USD 2.8 million and extended its cash runway into late 2027.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
7h ago
